Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026
Company Deals

Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio

Fineline Cube Apr 8, 2026
Company Deals

Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment

Fineline Cube Apr 8, 2026
Company Deals

Genesis MedTech Acquires Controlling Stake in TUGE Healthcare, Gaining China’s First Domestic 4K+3D+Fluorescence Endoscopic Platform

Fineline Cube Apr 7, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications

Fineline Cube Apr 8, 2026
Company Drug

Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data

Fineline Cube Apr 8, 2026
Company Drug

SinoMab BioScience Receives NMPA Approval for Phase I Study of Atopic Dermatitis Drug SM17

Fineline Cube Sep 12, 2023

Hong Kong-based biotechnology company SinoMab BioScience Ltd (HKG: 3681) has received approval from the National...

Company

Merck & Co. Becomes First Multinational to Register Unit in Hainan’s Lecheng Pilot Zone

Fineline Cube Sep 12, 2023

US pharmaceutical major Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK) has officially registered a...

Company Drug

Haisco Pharmaceutical Gets NMPA Approval for HSK21542 Chronic Pruritus Clinical Study

Fineline Cube Sep 12, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received approval...

Company Drug

ImmuneOnco’s IMM2510 and IMM27M Achieve Milestones in Phase I Clinical Trials

Fineline Cube Sep 12, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the completion of patient enrollment for...

Company Drug

CDE Indicates BTD Status for Visirna’s VSA001, Sperogenix’s Vamorolone, and Zai Lab’s Efgartigimod

Fineline Cube Sep 11, 2023

The Center for Drug Evaluation (CDE) website has indicated that Visirna Therapeutics’ novel siRNA therapy...

Company Deals

Shanghai Junshi Biosciences to Acquire Stake in Anlingke Biopharmaceutical for Cancer Therapy Programs

Fineline Cube Sep 11, 2023

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced its intention to...

Company Deals

Broncus Medical Inc. to Acquire Fibernova Holding Corporation for USD 2.7 Million

Fineline Cube Sep 11, 2023

Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations...

Company Medical Device

Lepu Medical Technology Receives NMPA Approval for MemoSorb Biodegradable PFO Occluder

Fineline Cube Sep 11, 2023

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...

Company Deals

EA Pharma and TransThera Sciences Collaborate on GI and Liver Disease Therapies

Fineline Cube Sep 11, 2023

Japan-based EA Pharma Co., Ltd and China-headquartered TransThera Sciences (Nanjing) Inc. have jointly announced the...

Company Deals

GRIT Biotechnology Secures RMB 400 Million in Series B Financing to Advance TIL Pipeline

Fineline Cube Sep 11, 2023

China-based GRIT Biotechnology has announced the completion of a Series B financing round, raising RMB...

Company Deals

Oriomics Secures Series B+ Funding to Advance Liver and Digestive Cancer Screening

Fineline Cube Sep 11, 2023

Hangzhou-based Oriomics, a specialist in cancer screening based on circulating tumor DNA (ctDNA) methylation detection,...

Company Drug

Sichuan Kelun Pharmaceutical Submits Biosimilar Cetuximab for NMPA Approval

Fineline Cube Sep 11, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), through its innovative drug development subsidiary Sichuan Kelun-Biotech...

Company Deals

Biotyx Medical Secures Over RMB 200 Million in Series B Financing for Iron-Based Stents

Fineline Cube Sep 11, 2023

China-based Biotyx Medical (Shenzhen) Co.,Ltd, known as the world’s only developer of iron-based absorbable stents,...

Company Drug

United Laboratories’ UBT251 Receives Tacit Approval for NAFLD Clinical Study in China

Fineline Cube Sep 11, 2023

Hong Kong firm United Laboratories International Holdings Ltd (HKG: 3933) has announced that its Category...

Company Drug

Abbisko Therapeutics Receives EMA Approval for Phase III Study of Pimicotinib for TGCT

Fineline Cube Sep 11, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...

Company Drug

AriBio Files for Phase III Clinical Trial Approval in China for Alzheimer’s Drug AR1001

Fineline Cube Sep 11, 2023

South Korean clinical-stage biotech AriBio Co. has announced the filing for Phase III clinical trial...

Company Drug

Allist Pharmaceuticals and ArriVent Biopharma Release Promising Interim Data on Furmonertinib for NSCLC

Fineline Cube Sep 11, 2023

Shanghai-based biotech Allist Pharmaceuticals Co., Ltd and its US partner ArriVent Biopharma Inc. have jointly...

Company Deals

iotaSciences Partners with Quantum Design China for Single-Cell Handling Platform Distribution

Fineline Cube Sep 11, 2023

UK-based cell-line engineering firm iotaSciences has announced an exclusive partnership with Quantum Design China, a...

Company Drug

BMS Announces Positive Outcomes for BMS-986278 in Progressive Pulmonary Fibrosis Study

Fineline Cube Sep 11, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) has released the final results from a Phase II trial...

Company Deals

Eurofarma Invests in Abcuro as Part of $100 Million Disruptive Startups and Biotech Initiative

Fineline Cube Sep 11, 2023

Brazil-based multinational company (MNC) Eurofarma has announced an investment in US immunotherapy developer Abcuro as...

Posts pagination

1 … 456 457 458 … 647

Recent updates

  • Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications
  • Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data
  • Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders
  • Sanofi’s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis
  • Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications

Company Drug

Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data

Others

Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders

Company Drug

Sanofi’s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.